Royce & Associates LP lowered its stake in shares of RadNet, Inc. (NASDAQ:RDNT – Free Report) by 6.0% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 198,494 shares of the medical research company’s stock after selling 12,775 shares during the period. Royce & Associates LP owned approximately 0.25% of RadNet worth $13,684,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in RDNT. SteelPeak Wealth LLC grew its position in RadNet by 0.6% during the third quarter. SteelPeak Wealth LLC now owns 25,251 shares of the medical research company’s stock worth $1,741,000 after buying an additional 151 shares in the last quarter. Arizona State Retirement System raised its holdings in RadNet by 0.9% in the 2nd quarter. Arizona State Retirement System now owns 18,203 shares of the medical research company’s stock valued at $1,123,000 after acquiring an additional 160 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in RadNet by 1.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 10,303 shares of the medical research company’s stock valued at $710,000 after acquiring an additional 175 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in RadNet by 2.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,392 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 207 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of RadNet by 10.6% in the 3rd quarter. GAMMA Investing LLC now owns 2,321 shares of the medical research company’s stock worth $160,000 after acquiring an additional 222 shares during the period. Institutional investors own 77.90% of the company’s stock.
RadNet Price Performance
Shares of RadNet stock opened at $76.89 on Tuesday. The firm has a market cap of $6.06 billion, a P/E ratio of 140.82 and a beta of 1.42. The firm’s 50-day simple moving average is $72.84 and its 200-day simple moving average is $65.53. RadNet, Inc. has a twelve month low of $50.82 and a twelve month high of $85.84. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.48 and a current ratio of 1.49.
RadNet (NASDAQ:RDNT – Get Free Report) last posted its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.08. The firm had revenue of $638.26 million during the quarter, compared to analyst estimates of $639.97 million. RadNet had a negative net margin of 0.94% and a positive return on equity of 3.14%. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.20 earnings per share. As a group, research analysts expect that RadNet, Inc. will post 0.56 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on RDNT. Truist Financial lifted their price objective on RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Barclays boosted their price objective on RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research report on Friday, August 28th. Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a research note on Wednesday, November 4th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Finally, KeyCorp raised their target price on RadNet from $92.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, RadNet presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.67.
Read Our Latest Stock Report on RDNT
Insider Activity
In other news, EVP Mital Patel sold 44,661 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $78.51, for a total value of $3,506,335.11. Following the completion of the transaction, the executive vice president directly owned 155,514 shares of the company’s stock, valued at approximately $12,209,404.14. This represents a 22.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.14% of the company’s stock.
About RadNet
RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
Read More
- Five stocks we like better than RadNet
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNT – Free Report).
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
